Objective: The aim of this study was to evaluate the effects of psyllium in type 2 diabetic patients.
Design: The study included three phases: phase 1 (1 week), phase 2 (treatment, 14 g fibre/day, 6 weeks) and phase 3 (4 weeks). At the end of each phase a clinical evaluation was performed after the ingestion of a test breakfast of 1824.2 kJ (436 kcal). Measurements included concentrations of blood glucose, insulin, fructosamine, GHbA1c, C-peptide and 24 h urinary glucose excretion. In addition, uric acid, cholesterol and several mineral and vitamin concentrations were also evaluated.
Setting: The study was performed at the Department of Pharmacology, Toxicology and Nursing at the University of León (Spain).
Subjects: Twenty type 2 diabetic patients (12 men and 8 women) participated in the study with a mean age of 67.4 y for men and 66 y for women. The mean body mass index of men was 28.2 kg/m2 and that of women 25.9 kg/m2.
Results: Glucose absorption decreased significantly in the presence of psyllium (12.2%); this reduction is not associated with an important change in insulin levels (5%). GHbA1c, C-peptide and 24 h urinary glucose excretion decreased (3.8, 14.9 and 22.5%, respectively) during the treatment with fibre (no significant differences) as well as fructosamine (10.9%, significant differences). Psyllium also reduced total and LDL cholesterol (7.7 and 9.2%, respectively, significant differences), and uric acid (10%, significant difference). Minerals and vitamins did not show important changes, except sodium that increased significantly after psyllium administration.
Conclusions: The results obtained indicate a beneficial therapeutic effect of psyllium (Plantaben®) in the metabolic control of type 2 diabetics as well as in lowering the risk of coronary heart disease. We also conclude that consumption of this fibre does not adversely affect either mineral or vitamin A and E concentrations. Finally, for a greater effectiveness, psyllium treatment should be individually evaluated.
Dietary fibre has significant gastrointestinal effects and it is a mainstay of treatment for constipation and haemorrhoids. Insoluble fibre is most effective for the treatment of these pathologies and an increased intake of soluble dietary fibre appears to benefit patients with diabetes mellitus (Gray, 1995).
The advantages of high-fibre diets for diabetic patients have been said to include lowering of serum lipids, assisted weight reduction and maintenance, and lowering of blood glucose levels (Kiehm et al, 1976; Anderson 1985a, b).
It is especially the gel-forming, water-soluble dietary fibre components such as guar gum, pectin and psyllium that have beneficial effects on carbohydrate metabolism (Jenkins et al, 1977; Chuang et al, 1992; Ellis et al, 1991; Fairchild et al, 1996; Gatenby et al, 1996; Wursch & Pi-Sunyer, 1997).
Psyllium or ispaghula husk (the husk of the seeds of Plantago ovata) is a mixture of neutral and acid polysaccharides with a rest of galacturonic acid. The polysaccharides are built up from the monomers D-xylose and L-arabinose, and ispaghula husk contains 67% pentosanes. Ispaghula husk is a gel-forming (water-soluble) fibre which has been used in treatment for constipation for many years. During the last two decades, several studies have been carried out to investigate whether ispaghula interferes with normal intestinal absorption of carbohydrate in healthy volunteers (Jarjis et al, 1984; Sierra et al, 2001) and in type 1 (Florholmen et al, 1982; Uribe et al, 1985) and type 2 diabetic patients (Sartor et al, 1981; Jarjis et al, 1984; Pastors et al, 1991). The effect of psyllium on fasting plasma cholesterol in hypercholesterolaemic patients has also been evaluated (Bell et al, 1989) and in obese and diabetic patients (Frati-Munari et al, 1983). The results obtained in these studies indicate that, in general, ispaghula administration yields to a decrease in glycaemia, insulinaemia and cholesterolaemia, but Jarjis et al, (1984) failed to detect significant glucose blunting.
In the present study we have evaluated the therapeutic effect of psyllium on glycaemic control in type 2 diabetic patients treated with glibenclamide and under dietary regulations. The effect on the total serum cholesterol concentrations and the distribution of serum cholesterol between the high-density-lipoprotein (HDL) and the low-density-lipoprotein (LDL) was also established. In addition, several hepatic, renal and haematological parameters were evaluated.
Subjects and methods
Twenty type 2 diabetic patients (12 men and 8 women) participated in the study. The mean age of the men was 67.4 y (range 50–80 y) and that of the women 66 y (range 54–79 y). The mean body mass index (BMI) of men was 28.2 kg/m2 (range 25–29.6 kg/m2) and of women 25.9 kg/m2 (range 20–29.8 kg/m2).
The duration of diabetes in all the volunteers eligible for the study was between 2 and 30 y (mean 10.4 y) in men and between 2 and 18 y (mean 7 y) in women. Diabetes was treated in all patients with a sulphonylurea (glibenclamide) and by conventional dietary restrictions. The diet followed by the volunteers was the same for all of them during the study. This diet is recommended to diabetic patients by the Program of INSALUD (National Institute of Health) and contains 55% of carbohydrate, 30% of fat (10% of saturated fat), 15% of protein and 25 g of fibre per day.
All subjects were questioned to assess subjective gastrointestinal side effects of the fibre, if any, but not one of the patients communicated any adverse effect. Each subject had normal stool consistence and frequency. Four patients who suffered from constipation showed a clear improvement during the treatment with fibre. All the volunteers successfully completed the study.
The study was conducted on an outpatient basis. The volunteers had no history of gastrointestinal disease and other major illnesses, and each subject served as his own control. The protocol was approved by the Human Ethical Committee of the University and INSALUD of Léon, Spain, and performed in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from each subject.
Patients were admitted to an open study for its entire duration. The study protocol included three different phases (phase 1, phase 2 (treatment) and phase 3) and at the end of each phase, the therapeutic and dietary accomplishment were evaluated by the patient and one of the investigators.
The study began with a 1 week period (phase 1) over which subjects followed a diet for diabetes and received the sulphonylurea. This was followed by the phase 2 (treatment phase, 6 weeks) over which patients continued with the diet and the sulphonylurea, and also received 3.5 g of psyllium (one dose of Plantaben®, orange flavoured, sugar-free, Madaus, S.A., Spain) four times a day: before breakfast, lunch, afternoon snack and dinner (14 g of psyllium/day). Subjects were instructed to mix each fibre packet in 250 ml of water, followed by 50 ml water for glass cleaning, and to drink the mixture before each meal. Phase 3 (4 weeks) was carried out after a 2-week washout interval. As in the phase 1, subjects followed the diet and received sulphonylurea. During phases 1 and 3, the patients received the same volume of water (300 ml) as in phase 2 without psyllium before meals in order to avoid changes in gastric emptying.
A clinical examination was performed at the end of each phase. On each occasion, and after overnight fast, they ingested a standard breakfast (Ebeling et al, 1988) of 1824.2 kJ (436 kcal; 53% carbohydrate, 26% protein and 21% fat), which consisted of 80 g low-fat boiled ham, two slices (60 g) of white bread and 200 ml low-fat milk with non-sweetened black coffee. Before breakfast, one dose of the fibre was given.
Blood samples (7 ml) were drawn through a butterfly cannula placed in the forearm at −15, 0, 10, 20, 30, 45, 60, 75, 90 and 120 min after breakfast ingestion for blood glucose estimation, and at −15, 0, 30, 60, 90 and 120 min blood insulin concentrations were also determined. The values calculated at −15 and 0 min were averaged to obtain glucose and insulin fasting values.
Blood samples obtained at time 0 were also used to determine several biochemical parameters (uric acid, total, HDL and LDL cholesterol) as well as different minerals (calcium, phosphorous, sodium, potassium, magnesium, iron) and vitamins (A and E) whose blood levels can be modified by the presence of fibre. In addition, other parameters related to patient status were also determined: glycosylated haemoglobin (GHbA1c), fructosamine and C-peptide in serum as well as 24 h urinary glucose and C-peptide excretion. The urine was collected from ingesting the test breakfast until next morning.
Serum glucose was measured with the Schmidt method (Schmidt, 1961) using an autoanalyser (Hitachi, mod. 704, Tokyo, Japan). Insulin concentrations were determined with an immunoradiometric assay (IRMA assay kit, Biosource Europe, S.A., Nivelles, Belgium). Serum vitamin A and E were determined by high-pressure liquid chromatography (HPLC; Driskell et al, 1982). An enzymatic colorimetric method was used for the determination of cholesterol (Boehringer-Mannheim, GmbH, Mannheim, Germany). The HDL fraction was analysed after precipitation with magnesium chloride and dextrane sulphate (Finley et al, 1978). LDL cholesterol was calculated by the formula of Friedewald et al (1972). GHbA1c was determined by commercial ion-exchange chromatography (Quick-Step Fast Hemoglobin System®, Isolab Inc., Akron, OH, USA). Minerals and uric acid were determined by using an autoanalyser Hitachi, model 704 (Tokyo, Japan). Serum fructosamine was analysed in triplicate using the Cobas Fara II (Lloyd & Marples, 1984). Urinary glucose concentrations were evaluated by using an enzymatic method (Weatherburn & Logan, 1966). Finally, C-peptide was determined by RIA (Kuzuya et al, 1976).
During the study, except the 2 week washout interval, patients measured their diurnal blood glucose profile at home twice a week (on Tuesday and on Thursday). On these days six measurements were done (before and 90 min after breakfast, lunch and dinner) using Glucostix® (Miles Limited, Glamorgan, UK) test strips that were read with a Glucometer (Miles Laboratories Inc., Elkhart, IN, USA). The number of blood glucose determinations per patient was 132, during the three periods (12 in phase 1, 72 in phase 2, 48 in phase 3).
Arithmetic means and s.d.s were calculated from the results measured. The data obtained from the three phases were compared for statistical significance by Friedman's test, at P<0.05 and, when the results were significant, Wilcoxon pairwise comparisons with Bonferroni correction were used, except for capillary glycaemia, where Kruskal–Wallis test and Mann–Whitney U-test were employed. All analyses were performed by using the Statgraphics Plus for Windows 2.0 (Manugistic Inc., Rockville, MA, USA).
The extent of glucose absorption decreased in the presence of psyllium when mean values were considered (Table 1 and Figure 1). Differences in mean concentrations at different sampling times were significant, except when the values obtained at time 0 for phases 2 and 3 were compared. Significant differences were also established for mean concentrations among subjects. Cmax decreased nearly 10% in the phase 2 (treatment) curve when compared with the values obtained in the phases 1 and 3. The rate of glucose absorption was similar during phases 2 and 3 (tmax=60 min) and less than in phase 1 (tmax=75 min).
The area under the serum glucose concentration–time curve (AUC) was 12.2% lower in the presence of fibre than that obtained at the end of phase 1 and 11.9% lower than that obtained at the end of the phase 3 (significant differences, Wilcoxon's test).
When accumulated areas (AUCt, where t is the time over which AUC has been calculated) were considered, significant differences were also found between phases 1 and 3 data when compared with those obtained in the phase 2, except at 10 min between phases 2 and 3 (Wilcoxon's test).
Large interindividual variations were observed in glucose concentrations, with CV ranging from 18.7 to 31.9% (Table 1) and, because of this, it is important to evaluate individual curves (Figure 2a and b) in addition to mean curves (Figure 1). Thus, in 10 patients (numbers 1–10, Figure 2a), glucose concentrations and AUC values were clearly lower at the end of the phase 2 than at the end of phases 1 and 3, with AUC decreases up to 34%. Five volunteers (numbers 11–15) showed higher values during the phase 1 than during phases 2 and 3, and in three of them (numbers 11–13), the curves obtained in phases 2 and 3 were very similar. Finally, in five subjects (numbers 16–20) the three curves were very similar.
AUC decreased a 5% in phase 2 in comparison with the value obtained in phase 1, and it was 15% lower than in phase 3 (no significant differences, Friedman's test, at P<0.05). Mean curve shapes (Figure 3) were similar in the three phases.
The value of Cmax (Table 2) was lower in the presence of fibre (348.6 pmol/l) than in phases 1 (369.0 pmol/l) and 3 (394.8 pmol/l), but these differences were not significant.
The individual insulinaemic responses were very different, with CVs for the mean concentrations higher than those obtained for glucose. In our opinion, this fact reflects the different states of type 2 diabetes evolution in which patients can be. When phases 1 and 3 are compared, some patients show a high decrease in AUC mean values (up to 47.6%), while in others this value is scarcely modified or even increases (up to 45% in one patient).
Examining the corresponding curves it can be observed that nine patients showed low insulin concentration values. Five of them had high glucose levels (numbers 3, 4, 10, 11 and 16), reaching concentrations over 16.7 mmol/l; in four patients (numbers 9, 13, 14 and 20), the glucose concentrations were high, with values greater than 13.3 mmol/l; in the other volunteer (number 18), the glucose concentrations at the end of the curve were over the basal levels. Five volunteers (numbers 1, 5, 7, 8 and 19) show high insulin concentrations during the administration of psyllium, and these values were generally higher than in phase 1 and lower than in phase 3. The three curves were similar in three patients (numbers 2, 6 and 15), except in the last times in two of them (numbers 2 and 6). Finally, in two subjects (numbers 12 and 17), the insulin concentrations decreased in the presence of fibre, when compared with those obtained in phase 1, and were similar to the values shown in the phase 3 curve.
A total of 120, 678 and 441 values of postprandial glucose concentrations were obtained, corresponding respectively to phases 1, 2 (treatment) and 3 of the study. The same number of preprandial data were evaluated. In general, there was a good compliance, but one patient only measured the glucose concentrations during phase 1; another patient forgot 2 days during phase 2 and, finally, one patient failed one day during phase 3.
Taking into account the mean values (Table 3), fasting blood glucose was slightly lower (4.5%) during phases 2 and 3 than during phase 1 (no significant differences, Kruskall–Wallis test, at P<0.05). The mean preprandial values corresponding to lunch and dinner were also slightly lower and differences were not significant (Kruskall–Wallis test, at P<0.05).
Mean postprandial glucose levels decreased during phase 2: 10.2% vs phase 1 and 5.3% vs phase 3 (significant differences, Mann–Whitney U-test).
The mean postprandial glucose concentrations corresponding to breakfast, lunch and dinner were always lower during phase 2 than during phases 1 and 3. The decreases in these values were 13.8% in breakfast, 7.8% in lunch and 8.2% in dinner (phase 2 vs phase 1), and 4.0% in breakfast, 6.7% in lunch and 4.4% in dinner (phase 2 vs phase 3). Significant differences were found between postprandial capillary glycaemia obtained after breakfast between phases 1 and 2. Important interindividual variations were also found in this parameter. In this way, some patients show decreases for postprandial glycaemia close to 30%, while in two subjects this parameter is scarcely modified.
Other parameters related to diabetes
Table 4 summarises several parameters related to diabetes. The treatment with fibre reduced slightly glycosylated haemoglobin (GHbA1c; 3.8% vs phase 1 and 5.5% vs phase 3), although no significant differences were observed. Similar results were obtained with fructosamine (fell by 10.9% on fibre vs phase 1 and by 7.8% vs phase 3) and with blood C-peptide (fell by 14.9% on fibre vs phase 1 and by 10% vs phase 3). The statistical evaluation showed significant differences for fructosamine when we compared the value obtained in phase 2 with those recorded in phases 1 and 3. In these parameters important interindividual variations were observed.
Twenty-four hour urinary glucose excretion was 22.5% lower at the end of the treatment than in phase 1 and 14.6% than in phase 3, however, significant differences (Wilcoxon's test) were only found between the phases 2 and 3. In this case, interindividual variations were even greater.
Serum total cholesterol concentrations decreased significantly under psyllium treatment by 7.7% and by 6.2% in comparison with phases 1 and 3, respectively. In the same way, LDL cholesterol fell by 9.2 and 7.7%, respectively (significant differences, Wilcoxon's test). HDL cholesterol remained unchanged during phase 2 (no significant differences, Friedman's test, at P<0.05). Psyllium administration also reduced uric acid (10%, significant difference, Wilcoxon's test).
Finally, other variables, including potassium, calcium, phosphorous, iron and vitamin A, showed no significant changes during the three phases (no significant differences, Friedman's test, at P<0.05). An increase in the levels of magnesium and vitamin E was found when data of phases 2 and 3 were compared (significant differences, Wilcoxon's test). Sodium levels also showed an increase between phase 2 and phases 1 and 3 (significant difference, Wilcoxon's test).
The effects of sustained fibre supplementation on glycaemic control in subjects with diabetes mellitus have been examined with considerable variations in results. The data are somewhat difficult to evaluate because of differences in population, fibre type, diet and study design (Weinstock & Levine, 1988).
Rendell (2000) indicates that improvement in glucose tolerance produced by consumption of viscous fibre is due to slower absorption of carbohydrate rather than malabsorption. Intimate mixing, allowing physical interaction between food and fibre, seems to be important in converting the carbohydrate to what might be termed a slow-release form.
Wolever et al (1991) demonstrated in normal and in type 2 diabetic patients that psyllium reduced the glycaemic response to a flaked bran cereal test meal when the fibre supplement was sprinkled onto the top of the cereal or incorporated into the flakes, but not when it was taken before the cereal. Despite this fact, in the present study the fibre was taken dispersed in water because psyllium incorporation in a meal (by sprinkling it) would make it, in most cases, unpalatable, and because this is the usual way any patient would prepare an oral treatment with a therapeutic fibre.
The mechanism of action of gel forming fibre is related to the ability to increase the viscosity of the gastrointestinal contents and thus interfere with motility and absorption (Hopman et al, 1988). Several authors (Holt et al, 1979; Sandhu et al, 1987) have demonstrated an inhibitory effect of dietary fibre on gastric emptying, but others could not prove it (Lawaetz et al, 1983; Lembcke et al, 1984). Hopman et al (1988) showed that glucomannan affects absorption within the intestine in a study carried out in patients with previous gastric surgery, and this is in agreement with the results obtained in several animal studies (Elsenhans et al, 1980,1981,1984; Johnson & Gee, 1981).
We found that psyllium, under the preparation used in this study, decreased significantly postprandial blood glucose concentrations in type 2 diabetic patients. It appears that this fact can show the best effect of psyllium. Earlier studies reported that psyllium reduced fasting serum glucose concentrations in individuals with type 2 diabetes (Fagerberg, 1982) and in type 2 diabetic patients with chronic portal-systemic encephalopathy (Uribe et al, 1985). Other studies demonstrated that different preparations of ispaghula husk lowered postprandial serum glucose concentrations in type 1 (Florholmen et al, 1982), in type 2 diabetic patients (Sartor et al, 1981; Pastors et al, 1991; Anderson et al, 1999), in healthy volunteers (Sierra et al, 2001) and in both healthy and type 2 diabetic subjects (Jarjis et al, 1984). Fibre doses used were different, ranging from 3.6 g administered with breakfast (Florholmen et al, 1982) to 35 g per day administered as a dietary supplement (Uribe et al, 1985). In contrast, no significant differences were found after a 50 g glucose load administered with 3.5 or 7 g fibre to healthy subjects (Jarjis et al, 1984).
The mean decrease of Cmax obtained in this study after the administration of psyllium (10%) was similar to that reported by Sartor et al (1981) after a standardized breakfast (9%), and lower than the indicated by Pastors et al (1991) at breakfast (14%) and at dinner (20%), and by Sierra et al (2001) in healthy subjects after a glucose load (15.5%).
Results obtained with guar gum are variable. Several authors report no modifications in glycaemia or a modest improvement of glycaemic control (Botha et al, 1981; Carroll et al, 1981; Lim et al, 1990; Stahl & Berger, 1990), while others indicate significant decreases (Smith & Holm, 1982; Fuessl et al, 1987; Chuang et al, 1992; Fairchild et al, 1996; Gatenby et al, 1996; Brenelli et al, 1997), some of them similar to the value indicated in this paper (10.1%, Chuang et al, 1992a, b) and others higher (50%, Fuessl et al, 1987; 35%, Brenelli et al, 1997).
In relation to insulin, the mean decrease we have found when fibre is administered is not significant, although we think that this may be due to the fact that patients had had diabetes for different lengths of time. This result is similar to that obtained by Jarjis et al (1984) in healthy and in type 2 diabetic volunteers. Pastors et al (1991) found significant decreases for insulin after the administration of psyllium in type 2 diabetic patients, with a reduction (12%) higher than the reported in this study (5%). We have also found in a previous study (Sierra et al, 2001) carried out in healthy volunteers, a significant and higher reduction of insulin concentrations (36.1%) after the administration of ispaghula husk.
These differences observed in insulin concentrations after the administration of psyllium, have also been reported with guar gum: several authors found no significant (Groop et al, 1986,1993) or minimum (Stahl & Berger, 1990) changes while others indicate significant differences (Chuang et al, 1992; Fairchild et al, 1996; Gatenby et al, 1996).
In relation to other parameters related to diabetes (GhbA1c, fructosamine, C-peptide concentrations in blood and in urine and glucose in urine), for all of them, we have obtained a decrease in their concentrations in the presence of fibre, which was significant for fructosamine. This last fact is important because, due to the relatively short duration of this study, fructosamine is a better marker than GhbA1c. This reduction might be due to psyllium's ability to reduce hunger feelings and energy intake (Rigaud et al, 1998). We have no data available from other authors about how psyllium modifies these parameters. The results obtained with other soluble fibres such as guar gum are variable. Thus, Stahl and Berger (1990) found no significant differences in glycosilated haemoglobin after the administration of 15 g of guar gum daily during 3 months; Jones et al (1985), after the administration of 10 g/day during 2 months, obtained a significant fall in GhbA1c levels, without significant changes in 24 h urinary glucose excretion. Behall (1990) observed that guar gum significantly reduced blood C-peptide concentrations after the administration of 31.7 g fibre per day during 6 months and Holman et al (1987) obtained no significant changes in blood C-peptide and GhbA1c concentrations after the administration of 15 g/day during 8 weeks.
Mean reductions obtained in total and in LDL cholesterol (7.7 and 9.2%, respectively, significant differences) were slightly higher than those showed by Bell et al (1989) in hypercholesterolaemic patients (4.8% reduction in total cholesterol level and 8.2% in LDL cholesterol) after a treatment with 10.2 g psyllium daily during 12 weeks. The reduction observed for LDL cholesterol by Davidson et al (1998) in hypercholesterolaemic patients after being treated with 10.2 g psyllium per day during 24 weeks was also slightly lower (5.3%) than our value. On the other hand, our results were slightly lower than those found by Anderson et al (1999) in men with type 2 diabetes and hypercholesterolaemia after 8 weeks receiving 10.2 g psyllium daily. Romero et al (1998) observed that LDL cholesterol concentrations were reduced by an average of 22.6 and 26% after administering 1.3 g/day of psyllium to healthy volunteers. In the same way, other authors (Rodríguez-Morán et al, 1998; Segawa et al, 1998) found a significant reduction in total and LDL cholesterol.
In relation to HDL cholesterol, we did not found significant changes in this parameter after the administration of fibre. Similar results were shown by other authors (Davidson et al, 1998; Romero et al, 1998). However, Rodríguez-Morán et al (1998) observed a significant increase in this parameter after the administration of 15 g psyllium daily to type 2 diabetic patients.
Results obtained with guar gum are, again, contradictory. In this way, Jones et al (1985) found no changes in lipid levels after the administration of this fibre, while other authors obtained significant reductions in LDL cholesterol concentrations without changes in HDL cholesterol (Holamn et al, 1987) or with a significant decrease in total cholesterol (Blake et al, 1997).
It has been suggested that deficiencies of calcium, iron, trace metals, certain vitamins and possibly other nutrients may occur after prolonged periods of high fibre intake (Nuttall, 1983; American Diabetes Association, 1987).
The slight decrease observed in the mean level of uric acid at the end of the psyllium phase in relation to the other two phases is significant in both cases. We have no data obtained by other authors for comparison and we think that further studies are required in order to determine whether the use of psyllium would be advantageous for the treatment of hyperuricaemic patients.
Results obtained in the present study on mineral and vitamin levels indicate that psyllium does not significantly modify serum concentrations when mean phase 2 values were compared with those obtained in phase 1, except that sodium increases significantly during the administration of psyllium, although the differences in concentration are low. We have no data available from other authors about how psyllium modifies these parameters. Chuang et al (1992) found that sodium, potassium, chloride, magnesium and calcium levels showed no significant changes during the treatment with guar gum (8 weeks).
Behall (1990) did not detect apparent changes in mineral balance (calcium, magnesium, iron, copper and zinc), with the exception of a negative manganese balance, after carboxymethyl cellulose administration. In this study, carboxymethyl cellulose gum, karaya gum and locust bean gum were consumed by the patients during 4 weeks each (19.5 g of fibre per day). The author, in a second study (Behall et al, 1989), administered 31.7 g guar gum per day during 6 months and found that mineral balance was not affected for iron, copper, zinc, calcium, manganese or magnesium.
Taking into account the results obtained in the present study, those found in an earlier study carried out in healthy subjects (Sierra et al, 2001) and according to Chuang et al (1992), we conclude that psyllium treatment effectiveness should be evaluated individually in each subject with the purpose of establishing the most adequate dose and administration regime and a greater efficiencyTable 5Figure 4aFigure 4b.
American Diabetes Association. 1987 Nutritional recommendations and principles for individuals with diabetes mellitus: 1986 Diabetes Care 10: 126–132
Anderson JW . 1985a Physiological and metabolic effects of dietary fiber Fed. Proc 44: 2902–2906
Anderson JW . 1985b High-fiber diets for obese diabetic men on insulin therapy: short-term and long-term effects Curr. Top. Nutr. Dis 14: 49–53
Anderson JW, Allgood LD, Turner J, Oeltgen PR, Daggy BP . 1999 Effects of psyllium on glucose and serum lipid responses in men with type 2 diabetes and hypercholesterolemia Am. J. Clin. Nutr 70: 466–473
Behall KM . 1990 Effect of soluble fibers on plasma lipids, glucose tolerance and mineral balance Adv. Exp. Med. Biol 270: 7–16
Behall KM, Scholfield DJ, McIvor ME, Van Duyn MS, Leo TA, Michnowski JE, Cummings CC, Mendeloff AI . 1989 Effect of guar gum on mineral balances in NIDDM adults Diabetes Care 12: 357–364
Bell LP, Hectorne K, Reynolds H, Balm TK, Hunninghake DB . 1989 Cholesterol-lowering effects of psyllium hydrophilic mucilloid. Adjunct therapy to a prudent diet for patients with mild to moderate hypercholesterolemia JAMA 261: 3419–3423
Blake DE, Hamblett CJ, Frost PG, Judd PA, Ellis PR . 1997 Wheat bread supplemented with depolymerized guar gum reduces the plasma cholesterol concentration in hypercholesterolemic human subjects Am. J. Clin. Nutr 65: 107–113
Botha AP, Steyn AF, Esterhuysen AJ, Slabbert M . 1981 Glycosylated hemoglobin, blood glucose and serum cholesterol levels in diabetics treated with guar gum S. Afr. Med. J 59: 333–334
Brenelli SL, Campos SD, Saad MJ . 1997 Viscosity of gums in vitro and their ability to reduce postprandial hyperglycemia in normal subjects Braz. J. Med. Biol. Res 30: 1437–1440
Carroll DG, Dykes V, Hodgson W . 1981 Guar gum is not a panacea in diabetes management NZ Med. J 93: 292–294
Chuang LM, Jou TS, Yang WS, Wu HP, Huang SH, Tai TY, Lin BJ . 1992 Therapeutic effect of guar gum in patients with non-insulin-dependent diabetes mellitus J Formos. Med. Assoc 91: 15–19
Davidson MH, Maki KC, Kong JC, Dugan LD, Torri SA, Hall HA, Drennan KB, Anderson SM, Fulgoni VL, Saldanha LG, Olson BH . 1998 Long-term effects of consuming foods containing psyllium seed husk on serum lipids in subjects with hypercholesterolemia Am. J. Clin. Nutr 67: 367–376
Driskell WJ, Neese JW, Bryant CC, Bashor MM . 1982 Measurement of vitamin A and vitamin E in human serum by high-performance liquid chromatography J. Chromatogr 231: 439–444
Ebeling P, Yki-Härvinen H, Aro A, Helve E, Sinisalo M, Koivisto VA . 1988) Glucose and lipid metabolism and insulin sensitivity in type 1 diabetes: the effect of guar gum Am. J. Clin. Nutr 48: 98–103
Ellis PR, Dawoud FM, Morris ER . 1991 Blood glucose, plasma insulin and sensory responses to guar-containing wheat breads: effects of molecular weight and particle size of guar gum Br. J. Nutr 66: 363–379
Elsenhans B, Süfke U, Blume R, Caspary WF . 1980 The influence of carbohydrate gelling agents on rat intestinal transport of monosaccharides and neutral amino acids in vitro Clin. Sci 59: 373–380
Elsenhans B, Süfke U, Blume R, Caspary WF . 1981 In vitro inhibition of rat intestinal surface hydrolisis of disaccharides and dipeptides by guaran Digestion 21: 98–103
Elsenhans B, Zenker D, Caspary WF, Blume R . 1984 Guaran effect on rat intestinal absorption Gastroenterology 86: 645–653
Fagerberg SE . 1982 The effects of a bulk laxative (Metamucil) on fasting blood glucose, serum lipids and other variables in constipated patients with non-insulin dependent adult diabetes Curr. Ther. Res 31: 165–172
Fairchild RM, Ellis PR, Byrne AJ, Luzio SD, Mir MA . 1996 A new breakfast cereal containing guar gum reduces postprandial plasma glucose and insulin concentrations in normal-weight human subjects Br. J. Nutr 76: 63–73
Finley PR, Schifman RB, Williams RJ, Lichti DA . 1978 Cholesterol in high-density lipoprotein: use of Mg2+ dextran sulphate in its enzymatic measurement Clin. Chem 24: 931–933
Florholmen J, Arvidsson-Lenner R, Jorde R, Burhol PG . 1982 The effect of Metamucil on postprandial blood glucose and plasma gastric inhibitory peptide in insulin-dependent diabetics Acta Med. Scand 212: 237–239
Frati-Munari AC, Fernandez-Harp JA, Becerril M, Chavez-Negrete M, Bañales-Ham M . 1983 Decrease in serum lipids, glycemia and body weight by Plantago psyllium in obese and diabetic patients Arch. Invest. Med. (Mex.) 14: 259–268
Friedewald WT, Levy RI, Fredrickson DS . 1972 Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin. Chem 18: 499–502
Fuessl HS, Williams G, Adrian TE, Bloom SR . 1987 Guar sprinkled on food: effect on glyceamic control, plasma lipids and gut hormones in non-insulin dependent diabetic patients Diabetes Med 4: 463–468
Gatenby SJ, Ellis PR, Morgan LM, Judd PA . 1996 Effect of partially depolymerized guar gum on acute metabolic variables in patients with non-insulin-dependent diabetes Diabetes Med 13: 358–364
Gray DS . 1995 The clinical uses of dietary fiber Am. Fam. Physician 51: 419–423
Groop PH, Groop L, Tötterman KJ, Fyhrquist F . 1986 Relationship between changes in GIP concentrations and changes in insulin and C-peptide concentrations after guar gum therapy Scand. J. Clin. Lab. Invest 46: 505–510
Groop PH, Aro A, Stenman S, Groop L . 1993 Long-term effects of guar gum in subjects with non-insulin dependent diabetes mellitus Am. J. Clin. Nutr 58: 513–518
Holman RR, Steemson J, Darling P . 1987 No glycemic benefit from guar administration in NIDDM Diabetes Care 10: 68–71
Holt S, Heading RC, Carter DC, Prescott LF, Tothill P . 1979 Effect of gel fiber on gastric emptying and absorption of glucose and paracetamol Lancet 1: 636–639
Hopman WPM, Houben PGMP, Speth PAJ, Lamers CBHW . 1988 Glucomannan prevents postprandial hypoglycaemia in patients with previous gastric surgery Gut 29: 930–934
Jarjis HA, Blackburn NA, Redfern JS, Read NW . 1984 The effect of ispaghula (Fybogel and Metamucil) and guar gum on glucose tolerance in man Br. J. Nutr 51: 371–378
Jenkins DJ, Leeds AR, Gassull MA, Cochet B, Alberti GM . 1977 Decrease in postprandial insulin and glucose concentrations by guar and pectin Ann. Intern. Med 86: 20–23
Jenkins DJA, Wolever TMS, Leeds AR, Gassull MA, Haisman P, Dilawari J, Goff DV, Metz GL, Alberti KG . 1978 Dietary fibers, fiber analogues, and glucose tolerance: importance of viscosity Br. Med. J 1: 1392–1394
Johnson IT, Gee JM . 1981 Effect of gel forming gums on the intestinal unstirred layer and sugar transport in vitro Gut 22: 398–403
Jones DB, Slaughter P, Lousley S, Carter RD, Jelfs R, Mann JI . 1985 Low-dose guar improves diabetic control J. R. Soc. Med 78: 546–548
Kiehm TG, Anderson JW, Ward K . 1976 Beneficial effects of a high carbohydrate, high fiber diet on hyperglycemic diabetic men Am. J. Clin. Nutr 29: 895–899
Kuzuya T, Saito T, Yoshida S . 1976 Human C-peptide immunoactivity (CPR) in blood and urine: evaluation of radioimmunoassay method and its clinical applications Diabetologia 12: 511–518
Lawaetz O, Blackburn AM, Bloom SR, Aritas Y, Ralphs DNL . 1983 Effect of pectin on gastric emptying and gut hormone release in the dumping syndrome Scand. J. Gastroenterol 18: 327–336
Lembcke B, Ebert R, Ptok M, Caspary WF, Creutzfeldt W, Schicha H, Emrich D . 1984 Role of gastrointestinal transit in the delay of absorption by viscous fibre (guar) Hepatogastroenterology 31: 183–186
Lim HS, Ee CH, Aw TC . 1990 Effects of low dose guar gum in non-insulin dependent diabetic patients Ann. Acad. Med. Singapore 19: 455–459
Lloyd D, Marples J . 1984 Simple colorimetry of glycated serum protein in a centrifugal analyzer Clin. Chem 28: 59–62
MacMahon M, Carless J . 1998 Ispaghula husk in the treatment of hypercholesterolaemia: a double-blind controlled study J. Cardiovasc. Risk 5: 167–172
Nuttall FQ . 1983 Diet and the diabetic patient Diabetes Care 6: 197–207
Oliver SD . 2000 The long-term safety and tolerability of ispaghula husk J. R. Soc. Health 120: 107–111
Pastors JG, Blaisdell PW, Balm TK, Asplin CM, Pohl SL . 1991 Psyllium fiber reduces rise in postprandial glucose and insulin concentrations in patients with non-insulin-dependent diabetes Am. J. Clin. Nutr 53: 1431–1435
Rendell M . 2000 Dietary treatment of diabetes mellitus New Engl. Med. J 342: 1440–1441
Rigaud D, Paycha F, Meulemans A, Merrouche M, Mignon M . 1998 Effect of psyllium on gastric emptying, hunger feeling and food intake in normal volunteers: a double blind study Eur. J. Clin. Nutr 52: 239–245
Rodríguez-Morán M, Guerrero-Romero F, Lazcano-Burciaga G . 1998 Lipid and glucose-lowering efficacy of Plantago psyllium in type II diabetes J. Diabetes Complications 12: 273–278
Romero AL, Romero JE, Galaviz S, Fernandez ML . 1998 Cookies enriched with psyllium or oat bran lower plasma LDL-cholesterol in normal and hypercholesterolemic men from Northern Mexico J. Am. Coll. Nutr 17: 601–608
Sandhu KS, el Samahi MM, Mena I, Dooley CP, Valenzuela JE . 1987 Effect of pectin on gastric emptying and gastroduodenal motility in normal subjects Gastroenterology 92: 486–492
Sartor G, Carlström S, Scherstén B . 1981 Dietary supplementation of fibre (Lunelax®) as a mean to reduce postprandial glucose in diabetics Acta Med. Scand. Suppl 656: 51–53
Schmidt FH . 1961 Die enzymatische Bestimmung von Glucose und Fructose nebeneinander Klin. Wschr 39: 1244–1247
Segawa K, Kataoka T, Fukuo Y . 1998 Cholesterol-lowering effects of psyllium seed associated with urea metabolism Biol. Pharm. Bull 21: 184–187
Sierra M, García JJ, Fernández N, Diez MJ, Calle AP, Sahagun AM Farmafibra Group. 2001 Effects of Ispaghula husk and guar gum on postprandial glucose and insulin concentrations in healthy subjects Eur. J. Clin. Nutr 55: 235–243
Smith U, Holm G . 1982 Effect of a modified guar gum preparation on glucose and lipid levels in diabetics and healthy volunteers Atherosclerosis 45: 1–10
Stahl M, Berger W . 1990 Comparison of guar gum, wheat bran and placebo on carbohydrate and lipid metabolism in type II diabetics Schweiz. Med. Wochenschr 120: 402–408
Uribe M, Dibildox M, Malpica S, Guillermo E, Villallobos A, Nieto L, Vargas F, Garcia Ramos G . 1985 Beneficial effect of vegetable protein diet supplemented with psyllium plantago in patients with hepatic encephalopathy and diabetes mellitus Gastroenterology 88: 901–907
Weatherburn MW, Logan JE . 1966 A simplified quantitative enzymatic procedure for glucose in urine Diabetes 15: 127–129
Weinstock RS, Levine RA . 1988 The role of dietary fiber in the management of diabetes mellitus Nutrition 4: 187–193
Wolever TM, Vuksan V, Eshuis H, Spadafora P, Peterson RD, Chao ES, Storey ML, Jenkins DJ . 1991 Effect of method of administration of psyllium on glycemic response and carbohydrate digestibility J. Am. Coll. Nutr 10: 364–371
Wursch P, Pi-Sunyer FX . 1997 The role of viscous soluble fiber in the metabolic control of diabetes: a review with special emphasis on cereals rich in beta-glucan Diabetes Care 20: 1774–1780
We wish to thank Madaus, S.A. Laboratory for the products supplied and for their economic collaboration in this study, the volunteers for their co-operation and Dr D Carriedo, Head of Service of the Hospital de León, Dr JC Alvarez and MA Gonzalez, members of the INSALUD Program for Diabetes Education and Control for their advice in the setting up and execution of this study
About this article
Cite this article
Sierra, M., García, J., Fernández, N. et al. Therapeutic effects of psyllium in type 2 diabetic patients. Eur J Clin Nutr 56, 830–842 (2002). https://doi.org/10.1038/sj.ejcn.1601398
- type 2 diabetic patients
- ispaghula husk
- dietary fibre
- capillary blood glucose
- metabolic variables
The effect of psyllium consumption on weight, body mass index, lipid profile, and glucose metabolism in diabetic patients: A systematic review and dose‐response meta‐analysis of randomized controlled trials
Phytotherapy Research (2020)
Psyllium husk intake and risk of type 2 diabetes: an evidence-based scientific and regulatory review of a qualified health claim conducted by the US Food and Drug Administration
Nutrition Reviews (2020)
The effects of psyllium supplementation on body weight, body mass index and waist circumference in adults: A systematic review and dose-response meta-analysis of randomized controlled trials
Critical Reviews in Food Science and Nutrition (2020)
International Journal for Vitamin and Nutrition Research (2019)
Alimentary Pharmacology & Therapeutics (2019)